HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HRX-0215 war sicher und gut verträglich bei gesunden Freiwilligen.
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
Er folgt auf Dr. Graham Dixon, der dem HepaRegeniX Beirat seit 2017 vorstand.
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.
Neue Daten belegen therapeutisches Potenzial der MKK4-Inhibition bei fortgeschrittenen Lebererkrankungen.
New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.
HepaRegeniX startet präklinische Kollaboration mit dem Netherlands Cancer Institute, um das Potenzial seines zweiten MKK4-Inhibitor HRX-0233 in der Kombinationstherapie gegen Krebs zu untersuchen
HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.